Alnylam Pharmaceuticals I... (ALNY)
NASDAQ: ALNY
· Real-Time Price · USD
449.02
6.29 (1.42%)
At close: Aug 15, 2025, 3:59 PM
448.00
-0.23%
After-hours: Aug 15, 2025, 05:30 PM EDT
Alnylam Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 773.69M | 594.19M | 593.17M | 500.92M | 659.83M | 494.33M | 439.72M | 750.53M | 318.75M | 319.29M | 335.04M | 264.31M | 224.82M | 213.26M | 258.54M | 187.63M | 220.55M | 177.57M |
Cost of Revenue | 142.95M | 71.04M | 102.82M | 85.91M | 68.67M | 65.98M | 85.86M | 84.31M | 85.37M | 54.87M | 51.27M | 41.12M | 40.81M | 35.63M | 37.66M | 32.66M | 38.76M | 31.06M |
Gross Profit | 630.74M | 523.15M | 490.35M | 415.01M | 591.15M | 428.36M | 353.86M | 666.22M | 233.38M | 264.42M | 283.77M | 223.19M | 184.01M | 177.63M | 220.87M | 154.97M | 181.8M | 146.5M |
Operating Income | -16.2M | 18.08M | -105.16M | -76.91M | 48.61M | -43.44M | -116.4M | 213.87M | -229.83M | -149.81M | -188.61M | -258.04M | -191.69M | -146.73M | -194.56M | -181.68M | -146.16M | -186.25M |
Interest Income | 27.49M | 28.67M | 31.02M | 32.15M | 29.18M | 29.64M | 30.41M | 25.43M | 21.07M | 18.66M | 14.08M | 7.82M | 1.9M | 1.01M | 495K | 225K | 409K | 450K |
Pretax Income | -35.36M | -41.6M | -193.96M | -108.66M | -11.17M | -63.59M | -137.69M | 150.74M | -274.21M | -172.36M | -207.02M | -405.94M | -274.67M | -239.36M | -260.3M | -204.24M | -188.33M | -199.28M |
Net Income | -66.28M | -57.48M | -83.76M | -111.57M | -16.89M | -65.94M | -137.87M | 147.75M | -276.02M | -174.1M | -207.49M | -405.92M | -277.4M | -240.34M | -258.46M | -204.51M | -189.56M | -200.29M |
Selling & General & Admin | 323.31M | 239.95M | 295.34M | 220.99M | 248.4M | 210.8M | 198.12M | 199.18M | 214.69M | 183.66M | 210.34M | 235.86M | 169.98M | 154.47M | 186.38M | 142.07M | 145.32M | 146.86M |
Research & Development | 323.62M | 265.12M | 300.17M | 270.93M | 294.14M | 261M | 272.14M | 253.18M | 248.53M | 230.57M | 262.04M | 245.37M | 205.71M | 169.89M | 229.05M | 194.57M | 182.63M | 185.9M |
Other Expenses | n/a | n/a | n/a | n/a | 1.3M | n/a | 1.98M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -140K | n/a |
Operating Expenses | 646.93M | 505.07M | 595.51M | 491.92M | 542.54M | 471.79M | 470.26M | 452.35M | 463.21M | 414.23M | 472.38M | 481.23M | 375.7M | 324.36M | 415.43M | 336.65M | 327.96M | 332.76M |
Interest Expense | 40.25M | 38.65M | 38.97M | 34.38M | 33.26M | 35.25M | 31.34M | 30.89M | 30.04M | 28.95M | 29.91M | 41.08M | 42.61M | 42.36M | 36.82M | 40.27M | 33.42M | 32.52M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 789.89M | 576.11M | 698.33M | 577.82M | 611.21M | 537.77M | 556.12M | 536.66M | 548.59M | 469.1M | 523.65M | 522.35M | 416.5M | 359.99M | 453.1M | 369.31M | 366.71M | 363.82M |
Income Tax Expense | 30.92M | 15.88M | -110.19M | 2.91M | 5.72M | 2.35M | 183K | 2.99M | 1.81M | 1.74M | 472K | -23K | 2.73M | 985K | -1.84M | 278K | 1.23M | 1.02M |
Shares Outstanding (Basic) | 129.68M | 129.68M | 128.59M | 128.59M | 126.73M | 126.14M | 125.61M | 125.22M | 124.66M | 124.11M | 123.27M | 122.17M | 120.9M | 120.17M | 119.77M | 118.9M | 117.77M | 117.08M |
Shares Outstanding (Diluted) | 129.68M | 129.68M | 128.59M | 128.59M | 126.73M | 126.14M | 125.61M | 131.34M | 124.66M | 124.11M | 123.27M | 122.17M | 120.9M | 120.39M | 119.77M | 119.14M | 117.77M | 117.08M |
EPS (Basic) | -0.51 | -0.44 | -0.65 | -0.87 | -0.13 | -0.52 | -1.1 | 1.18 | -2.21 | -1.4 | -1.68 | -3.32 | -2.29 | -2 | -2.16 | -1.72 | -1.61 | -1.71 |
EPS (Diluted) | -0.51 | -0.44 | -0.65 | -0.87 | -0.13 | -0.52 | -1.1 | 1.15 | -2.21 | -1.4 | -1.68 | -3.32 | -2.29 | -2 | -2.16 | -1.72 | -1.61 | -1.71 |
EBITDA | 18.83M | 11.46M | -140.91M | -60.3M | 37.09M | -14.82M | -92.87M | 194.96M | -231M | -129.34M | -162.8M | -354.26M | -221.97M | -187.53M | -212.11M | -152.18M | -143.11M | -154.16M |
EBIT | 4.89M | -2.95M | -154.99M | -74.29M | 22.09M | -28.33M | -106.35M | 181.63M | -244.17M | -143.41M | -177.11M | -364.86M | -232.06M | -196.99M | -223.49M | -163.96M | -154.91M | -166.76M |
Depreciation & Amortization | 13.94M | 14.4M | 14.17M | 13.98M | 15M | 13.52M | 13.48M | 13.33M | 13.18M | 14.06M | 14.31M | 10.6M | 10.1M | 9.46M | 11.38M | 11.79M | 11.8M | 12.6M |